Burnout amongst workers is on the rise, with 38% of people in a 2022 study experiencing burnout at work, reporting feelings of exhaustion, reduced efficacy, and cynicism. Burnout has become particularly challenging for remote workers, with the same study finding that those working from home more than 80% of the time are the group most likely to experience this, with this group also receiving the lowest level of organisational support.
Belgium team to expand under Country Manager, Dr Pierre-Hervé Brun, providing CNS treatments to patients
Expansion of manufacturing facility in North Carolina will increase the number of patients who may benefit from the company's medicines
In order to attract top talent in the life science industry, you need to ensure you’re providing the best possible experience for your candidates, from the minute you post a job advert to the moment they’re offered the job, and even beyond. 7 in 10 jobseekers who receive a poor candidate experience will never want to work for that organisation again, with 72% also saying that they’d be likely to tell friends, colleagues, and family members about the experience.
Charles River Edinburgh has been awarded Top Employer UK status for 2023. This internationally recognised award is given to organisations that show a passion and commitment to enriching the world of work for their employees. This is the second consecutive year that CRL EDI has received this award!
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services
BOSTON, MA and UNIONDALE, NY, January 17, 2023 – Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp (NASDAQ:ANGN) under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.
AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc. (Nasdaq: IMGO), at a purchase price of $36.00 per share in cash, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 10, 2023, 31,307,028 shares of common stock of Imago were validly tendered and not withdrawn from the tender offer, representing approximately 89.2% of the total number of Imago’s outstanding shares on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.
- Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology
- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties
